Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$21.1M+284%$5.49M-61.3%$14.18M-50.9%$28.87M+2,187%$1.26M-95.2%
$108K-46.3%$201K+1,910%$10K-69.7%$33K+10.0%$30K-91.4%
$20.99M+297%$5.29M-62.7%$14.17M-50.8%$28.83M+2,240%$1.23M-95.3%
99.5%+3.1pp96.3%-3.6pp99.9%0.0pp99.9%+2.3pp97.6%-1.1pp
$12.76M+12.7%$11.32M-39.7%$18.76M+19.1%$15.75M+2.9%$15.3M-42.7%
$9.23M+5.4%$8.76M+15.2%$7.6M-18.7%$9.35M-19.5%$11.61M-64.0%
$22.1M+9.0%$20.27M-23.1%$26.37M+4.9%$25.13M-6.7%$26.94M-54.6%
-$996K+93.3%-$14.78M-21.3%-$12.19M-426%$3.74M+115%-$25.68M+21.6%
-4.7%+264pp-269.1%-183pp-85.9%-98.9pp12.9%+2,048pp-2,034.8%-1,912pp
$1.48M-12.3%$1.69M-4.1%$1.76M-8.5%$1.92M-35.3%$2.97M-5.0%
$1.54M+20.5%$1.28M-18.6%$1.57M-14.2%$1.83M-17.4%$2.22M-21.6%
-$1.04M+93.3%-$15.53M-21.6%-$12.77M-493%$3.25M+113%-$25.3M+25.1%
-4.9%+278pp-282.7%-193pp-90%-101pp11.3%+2,016pp-2,004.4%-1,877pp
$0.00+100%-$0.040.0%-$0.04-500%$0.01+114%-$0.07+22.2%
-$886K+94.0%-$14.66M-21.8%-$12.04M-408%$3.91M+115%-$25.5M+21.8%
-4.2%+263pp-266.9%-182pp-84.9%-98.4pp13.6%+2,034pp-2,020.8%-1,898pp
-$996K+93.3%-$14.78M-21.3%-$12.19M-426%$3.74M+115%-$25.68M+21.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Lexicon Pharmaceuticals's revenue?
Lexicon Pharmaceuticals (LXRX) generated $69.6M in revenue over the trailing twelve months, up 123.1% year over year.
Is Lexicon Pharmaceuticals profitable?
Lexicon Pharmaceuticals is not currently profitable: it reported a net loss of $26.1M over the trailing twelve months, a -37.5% net margin.
What are Lexicon Pharmaceuticals's profit margins?
Gross margin is 99.5% and operating margin is -34.8%, with a -37.5% net margin.
What is Lexicon Pharmaceuticals's earnings per share?
Lexicon Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.07.
Where does Lexicon Pharmaceuticals's income statement data come from?
Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.